Tetrodotoxin - WEX Pharmaceuticals

Drug Profile

Tetrodotoxin - WEX Pharmaceuticals

Alternative Names: 9401-TTX; Tectin; Tetrodin; Tocudin

Latest Information Update: 28 Nov 2016

Price : $50

At a glance

  • Originator Beijing Medical University; WEX Pharmaceuticals
  • Developer WEX Pharmaceuticals
  • Class Analgesics; Antiarrhythmics; Quinazolines
  • Mechanism of Action Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Cancer pain
  • Phase II Neuropathic pain; Pain
  • Preclinical Anaesthesia
  • Suspended Opioid abuse

Most Recent Events

  • 12 Oct 2016 Chemical structure information added
  • 29 Sep 2016 WEX Pharmaceutical completes the phase I WEX-001 trial in Healthy volunteers in Canada (before September 2016; WEX Pharmaceuticals website, September 2016)
  • 29 Sep 2016 WEX Pharmaceutical completes the phase I WEX-015 trial in Healthy volunteers in Canada (before September 2016; WEX Pharmaceuticals website, September 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top